[5-(Benzyl-{3-[benzyl-(6-{[6-(benzyl-tert-butoxycarbonyl-amino)-hexyl]-tert-butoxycarbonyl-amino}-hexanoyl)-amino]-2-oxo-propyl}-carbamoyl)-pentyl]-[6-(benzyl-tert-butoxycarbonyl-amino)-hexyl]-carbamic acid tert-butyl ester | 289889-17-4

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: [5-(Benzyl-{3-[benzyl-(6-{[6-(benzyl-tert-butoxycarbonyl-amino)-hexyl]-tert-butoxycarbonyl-amino}-hexanoyl)-amino]-2-oxo-propyl}-carbamoyl)-pentyl]-[6-(benzyl-tert-butoxycarbonyl-amino)-hexyl]-carbamic acid tert-butyl ester
• 英文别名: tert-butyl N-benzyl-N-[6-[[6-[benzyl-[3-[benzyl-[6-[6-[benzyl(tert-butoxycarbonyl)amino]hexyl-tert-butoxycarbonyl-amino]hexanoyl]amino]-2-oxo-propyl]amino]-6-oxo-hexyl]-tert-butoxycarbonyl-amino]hexyl]carbamate；tert-butyl N-benzyl-N-[6-[[6-[benzyl-[3-[benzyl-[6-[6-[benzyl-[(2-methylpropan-2-yl)oxycarbonyl]amino]hexyl-[(2-methylpropan-2-yl)oxycarbonyl]amino]hexanoyl]amino]-2-oxopropyl]amino]-6-oxohexyl]-[(2-methylpropan-2-yl)oxycarbonyl]amino]hexyl]carbamate
• CAS: 289889-17-4
• 化学式: C₇₅H₁₁₂N₆O₁₁
• 分子量: 1273.75
• InChiKey: APARLTWIKZMYLL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  13.4
• 重原子数：
  92
• 可旋转键数：
  46
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.59
• 拓扑面积：
  176
• 氢给体数：
  0
• 氢受体数：
  11

反应信息

• 作为反应物：
  描述：

  [5-(Benzyl-{3-[benzyl-(6-{[6-(benzyl-tert-butoxycarbonyl-amino)-hexyl]-tert-butoxycarbonyl-amino}-hexanoyl)-amino]-2-oxo-propyl}-carbamoyl)-pentyl]-[6-(benzyl-tert-butoxycarbonyl-amino)-hexyl]-carbamic acid tert-butyl ester 在 sodium tetrahydroborate 作用下， 以 乙醇 为溶剂， 反应 0.17h， 以65%的产率得到[5-(Benzyl-{3-[benzyl-(6-{[6-(benzyl-tert-butoxycarbonyl-amino)-hexyl]-tert-butoxycarbonyl-amino}-hexanoyl)-amino]-2-hydroxy-propyl}-carbamoyl)-pentyl]-[6-(benzyl-tert-butoxycarbonyl-amino)-hexyl]-carbamic acid tert-butyl ester
  参考文献：
  名称：

  New anti-HIV derivatives: synthesis and antiviral evaluation

  摘要：

  A small focused library of 18 compounds incorporating the motif 1,3-(N,N'-dibenzyl)diamino-2-propanol has been synthesized, using adapted synthetic methodologies. These series of compounds were evaluated for their in vitro anti-HIV activity on infected MT(4) cells (syncytium formation observation). Some of the new synthesized compounds show potent anti-HIV activities. EC(50) values for compounds (31, 40, 34, 37 and 46) range From 0.1 to 1 mu M. In order to determine at which level these new derivatives interfere with the HIV replicative cycle, inhibition assays on recombinant HIV protease and HIV integrase have been performed. None of the compounds were found active on these two enzymatic targets. Experiments are in progress in order to identify their biological target within the HIV replicative cycle. (C) 2000 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0968-0896(00)00055-9
• 作为产物：
  描述：

  6-氨基-1-己醇 在 重铬酸吡啶 、 potassium carbonate 、 (benzotriazo-1-yloxy)tris(dimethylamino)phosphonium hexafluorophosphate 、 三乙胺 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 、 乙腈 为溶剂， 反应 124.0h， 生成 [5-(Benzyl-{3-[benzyl-(6-{[6-(benzyl-tert-butoxycarbonyl-amino)-hexyl]-tert-butoxycarbonyl-amino}-hexanoyl)-amino]-2-oxo-propyl}-carbamoyl)-pentyl]-[6-(benzyl-tert-butoxycarbonyl-amino)-hexyl]-carbamic acid tert-butyl ester
  参考文献：
  名称：

  New anti-HIV derivatives: synthesis and antiviral evaluation

  摘要：

  A small focused library of 18 compounds incorporating the motif 1,3-(N,N'-dibenzyl)diamino-2-propanol has been synthesized, using adapted synthetic methodologies. These series of compounds were evaluated for their in vitro anti-HIV activity on infected MT(4) cells (syncytium formation observation). Some of the new synthesized compounds show potent anti-HIV activities. EC(50) values for compounds (31, 40, 34, 37 and 46) range From 0.1 to 1 mu M. In order to determine at which level these new derivatives interfere with the HIV replicative cycle, inhibition assays on recombinant HIV protease and HIV integrase have been performed. None of the compounds were found active on these two enzymatic targets. Experiments are in progress in order to identify their biological target within the HIV replicative cycle. (C) 2000 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0968-0896(00)00055-9